# Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

> **NCT02864992** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 337 (actual)

## Conditions studied

- Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
- Lung Adenocarcinoma Stage IIIB/IV

## Interventions

- **DRUG:** Tepotinib

## Key facts

- **NCT ID:** NCT02864992
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09-13
- **Primary completion:** 2022-05-16
- **Final completion:** 2026-04-30
- **Target enrollment:** 337 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02864992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02864992, "Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02864992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*